Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly

Adamson RJ. et al, (2023), Free Radical Biology and Medicine

Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.

Ong HW. et al, (2023), ACS Chem Neurosci

Target 2035 – an update on private sector contributions

Ackloo S. et al, (2023), RSC Medicinal Chemistry

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Smilde BJ. et al, (2022), BMC musculoskeletal disorders, 23

Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation

Chen Z. et al, (2022), Cell Death & Differentiation

Sequence and structural variations determining the recruitment of WNK kinases to the KLHL3 E3 ligase.

Chen Z. et al, (2022), The Biochemical journal

Ubiquitin ligases: guardians of mammalian development

Cruz Walma DA. et al, (2022), Nature Reviews Molecular Cell Biology

Target 2035-update on the quest for a probe for every protein

Mueller S. et al, (2021), RSC MEDICINAL CHEMISTRY

Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe.

Röhm S. et al, (2021), Journal of medicinal chemistry, 64, 13451 - 13474

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Ventura F. et al, (2021), Biomedicines, 9, 213 - 213

ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex

Williams E. et al, (2021), Biomedicines, 9, 129 - 129

DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity

Schröder M. et al, (2020), Journal of Medicinal Chemistry, 63, 10224 - 10234

Leveraging an Open Science Drug Discovery Model to Develop CNS Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma

Smil D. et al, (2020), Journal of Medicinal Chemistry

Sequence and structural variations determining the recruitment of WNK kinases to the KLHL3 E3 ligase

Chen Z. et al, (2020)

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.

Suebsuwong C. et al, (2020), European journal of medicinal chemistry, 200

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Ensan D. et al, (2020), Journal of medicinal chemistry, 63, 4978 - 4996

A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5

Hanke T. et al, (2020), ACS Chemical Biology

Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas

Fortin J. et al, (2020), Cancer Cell

Identification of a PGXPP degron motif in dishevelled and structural basis for its binding to the E3 ligase KLHL12

Chen Z. et al, (2020)

Janus kinase inhibition for autoinflammation in patients with DNASE2 deficiency

Hong Y. et al, (2020), Journal of Allergy and Clinical Immunology, 145, 701 - 705.e8

Load More

1
2
3
4
5
6

Include forthcoming?